Enterprise Europe Network

Anti-CD3 used in immuno-suppressive drugs for the treatment of leukaemia, offered to oncology researchers via licencing agreement

Country of origin:
Country: 
UNITED KINGDOM
Opportunity:
External Id: 
TOUK20201216001
Published
06/01/2021
Last update
05/01/2022
Expiration date
18/07/2022

Keywords

Partner keyword: 
Cytology, Cancerology, Oncology
Medical Research
Pharmaceutical Products / Drugs
Stem cell Technologies
Cellular and Molecular Biology
Other recombinant DNA
Monoclonal Antibodies and Hybridomas
Cellular and Molecular Biology
Oncology
Anatomy, Pathology, Immunology, Physiology
Research and experimental development on biotechnology
Other professional, scientific and technical activities n.e.c.
Other human health activities
EXPRESS YOUR INTEREST

Summary

Summary: 
A UK non-profit organisation is providing access to Anti-CD3 (Anti-Cluster of Differentiation) from its original source Cancer Research UK, to academia and life science industry. The Anti-CD3 antibody is used as a pan T-cell marker in the detection of T-cell populations and in immuno-suppressive drugs for the treatment of leukaemia and is offered to cancer researchers and scientists in academia and industry, via licensing agreement.

Description

Description: 

A UK non-profit organisation is providing access to Anti-CD3 from its original source Cancer Research UK, to academia and life science industry.

This antibody was created by Professor Peter Beverley, a pioneer in creating hybridomas from mice immunised against human lymphocytes, with Anti-CD3 being one of the first successful fusions. It is available for researchers studying leukaemia, lymphocytes or the role of CD3 in T cell antigen receptor (TCR) signal transduction events.

The UK company has been commercialising life science research tools created by scientists working in cancer research for more than 25 years and provide a service making a range of antibodies and markers more readily available worldwide, including Anti-CD3, which is available for researchers and companies working in oncology, immunology and more via licensing agreement.

Advantages & innovations

Cooperation plus value: 
This UK non-profit organisation has both monoclonal and recombinant rights to Anti-CD3. Since it was developed by Prof. Peter Beverley, over 20 research publications have been published using Anti-CD3 in application areas including oncology, immunology, stem cell biology, and cell signalling.

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
Type: Industry or academia Activity of partner: Life science research in leukaemia, lymphocytes or the role of CD3 Specific role of partner sought: Licensing of the Anti-CD3 marker to contribute to their research and development

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500